Exploring the binding sites of glycogen synthase kinase 3. identification and characterization of allosteric modulation cavities

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8461-8470

  Palomo, Valle ^a   Soteras, Ignacio ^a   Perez, Daniel I ^a   Perez, Concepción ^a   Gil, Carmen ^a   Campillo, Nuria Eugenia ^a   Martinez, Ana ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MANZAMINE A; N' DODECANOYL 1 ETHYL 4 HYDROXY 2 OXO 1,2 DIHYDROQUINOLINE3 CARBOHYDRAZIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING SITE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION;

ALLOSTERIC SITE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDRAZINES; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; QUINOLONES; SMALL MOLECULE LIBRARIES;

EID: 84055217601     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200996g     Document Type: Article

References (45)

1. Kannoji, A.; Phukan, S.; Sudher Babu, V.; Balaji, V. N. GSK3beta: a master switch and a promising target. Expert Opin. Ther. Targets 2008, 12, 1443-1455.
2. In Glycogen synthase kinase 3 (GSK-3) and its inhibitors; Martinez, A., Castro, A., Medina, M., Eds.; John Wiley & Sons: Hoboken, NJ, 2006.
3. Martinez, A. Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs. Med. Res. Rev. 2008, 28, 773-796.
4. Hooper, C.; Killick, R.; Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104, 1433-1439.
5. del Ser, T. Phase IIa clinical trial on Alzheimer's disease with NP12, a GSK-3 inhibitor. Alzheimer's Dementia 2010, 6, S147.
6. Martinez, A.; Perez, D. I. GSK-3 inhibitors: A ray of hope for the treatment of Alzheimer's disease? J. Alzheimers Dis. 2008, 15, 181-191.
7. Chico, L. K.; Van Eldik, L. J.; Watterson, D. M. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discovery 2009, 8, 892-909.
8. Cohen, P.; Goedert, M. GSK3 inhibitors: Development and therapeutic potential. Nat. Rev. Drug Discovery 2004, 3, 479-487.
9. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002, 22, 373-384.
10. Eglen, R. M.; Reisine, T. The current status of drug discovery against the human kinome. Assay Drug Dev. Technol. 2009, 7, 22-43.
11. Eglen, R.; Reisine, T. Drug discovery and the human kinome: Recent trends. Pharmacol. Ther. 2011, 130, 144-156.
12. McInnes, C.; Fischer, P. M. Strategies for the design of potent and selective kinase inhibitors. Curr. Pharm. Des. 2005, 11, 1845-1863.
13. Martinez, A.; Gil, C.; Perez, D. I. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. Int. J. Alzheimer's Dis. 2011, 2011, 280502.
14. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 2002, 45, 1292-1299.
15. Mazanetz, M. P.; Fischer, P. M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discovery 2007, 6, 464-479.
16. Conde, S.; Perez, D. I.; Martinez, A.; Perez, C.; Moreno, F. J. Thienyl and phenyl alpha-halomethyl ketones: New inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J. Med. Chem. 2003, 46, 4631-4633.
17. Perez, D. I.; Conde, S.; Perez, C.; Gil, C.; Simon, D.; Wandosell, F.; Moreno, F. J.; Gelpi, J. L.; Luque, F. J.; Martinez, A. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg. Med. Chem. 2009, 17, 6914-6925.
18. Perez, D. I.; Palomo, V.; Perez, C.; Gil, C.; Dans, P. D.; Luque, F. J.; Conde, S.; Martinez, A. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: Clues for specific design of new compounds. J. Med. Chem. 2011, 4042-4056.
19. Eldar-Finkelman, H.; Eisenstein, M. Peptide inhibitors targeting protein kinases. Curr. Pharm. Des. 2009, 15, 2463-2470.
20. Fraser, E.; Young, N; Dajani, R.; Franca-Koh, J.; Ryves, J.; Williams, R S.; Yeo, M.; Webster, M. T.; Richardson, C.; Smalley, M. J.; Pearl, L. H.; Harwood, A.; Dale, T. C. Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J. Biol. Chem. 2002, 277, 2176-2185.
21. Eldar-Finkelman, H.; Licht-Murava, A.; Pietrokovski, S.; Eisenstein, M. Substrate competitive GSK-3 inhibitors-Strategy and implications. Biochim. Biophys. Acta 2010, 1804, 598-603.
22. Shapira, M.; Licht, A.; Mlman, A.; Pick, C. G.; Shohami, E; Eldar-Finkelman, H. Role of glycogen synthase kinase-3 beta in early depressive behavior induced by mild traumatic brain injury. Mol. Cell. Neurosci. 2007, 34, 571-577.
23. Hamann, M.; Alonso, D.; Martin-Aparicio, E; Fuertes, A.; Perez-Puerto, M. J.; Castro, A.; Morales, S.; Navarro, M. L.; Del Monte-Millan, M.; Medina, M.; Pennaka, H.; Balaiah, A.; Peng, J.; Cook, J.; Wahyuono, S.; Martinez, A. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J. Nat. Prod. 2007, 70, 1397-1405.
24. Alonso, D.; Martinez, A. Marine compounds as a new source for glycogen synthase kinase 3 inhibitors. In Glycogen synthase kinase 3 (GSK-3) and its inhibitors; Martinez, A, Castro, A, Medina, M., Eds.; John Wiley & Sons: Hoboken, NJ, 2006; pp 307-331.
25. Peng, J. N; Kudrimoti, S.; Prasanna, S.; Odde, S.; Doerksen, R J.; Pennaka, H. K.; Choo, Y M.; Rao, K. V.; Tekwani, B. L.; Madgula, V.; Khan, S. I.; Wang, B.; Mayer, A M. S.; Jacob, M. R; Tu, L. C.; Gertsch, J.; Hamann, M. T. Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. J. Med. Chem. 2010, 53, 61-76.
26. Pérot, S.; Sperandio, O.; Miteva, M. A.; Camproux, A C.; Villoutreix, B. O. Druggable pockets and binding site centric chemical space: A paradigm shift in drug discovery. Drug Discovery Today 2010, 15, 656-667.
27. Schmidtke, P.; Souaille, C.; Estienne, F.; Baurin, N; Kroemer, R T. Large-scale comparison of four binding site detection algorithms. J. Chem. Inf. Model. 2010, 50, 2191-2200.
28. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J. Med. Chem. 2010, 53, 5858-5867.
29. Le Guilloux, V.; Schmidtke, P.; Tuffery, P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinf. 2009, 10, 168.
30. Schmidtke, P.; Le Guilloux, V.; Maupetit, J.; Tuffery, P. fpocket: online tools for protein ensemble pocket detection and tracking. Nucleic Acids Res. 2010, 38, W582-W589.
31. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 1999, 42, 2909-2919.
32. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormo, M.; Nilsson, Y.; Radesater, A. C.; Jerning, E.; Markgren, P. O.; Borgegard, T.; Nylof, M.; Gimenez-Cassina, A.; Hernandez, F.; Lucas, J. J.; Diaz-Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 2003, 278, 45937-45945.
33. Dajani, R.; Fraser, E.; Roe, S. M.; Young, N.; Good, V.; Dale, T. C.; Pearl, L. H. Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001, 105, 721-732.
34. Ibrahim, M. A.; Shilabin, A. G.; Prasanna, S.; Jacob, M.; Khan, S. I.; Doerksen, R. J.; Hamann, M. T. 2-N-Methyl modifications and SAR studies of manzamine A. Bioorg. Med. Chem. 2008, 16, 6702-6706.
35. Osolodkin, D. I.; Shulga, D. A.; Palyulin, V. A.; Zefirov, N. S. Interaction of manzamine A with glycogen synthase kinase 3beta: a molecular dynamics study. Russ. Chem. Bull., Int. Ed. 2010, 59, 1983-1993.
36. Licht-Murava, A.; Plotkin, B.; Eisenstein, M.; Eldar-Finkelman, H. Elucidating substrate and inhibitor binding sites on the surface of GSK-3beta and the refinement of a competitive inhibitor. J. Mol. Biol. 2011, 408, 366-378.
37. Martinez, A.; Gil, C.; Palomo, V.; Perez, C.; Perez, D. I. Moduladores alostericos de GSK-3 heterociclicos. P201131582
38. http://helix.nih.gov/Applications/maxcluster.html.
39. Biegert, A.; Soding, J. Sequence context-specific profiles for homology searching. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 3770-3775.
40. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
41. Chandonia, J. M.; Hon, G.; Walker, N. S.; Lo Conte, L.; Koehl, P.; Levitt, M.; Brenner, S. E. The ASTRAL Compendium in 2004. Nucleic Acids Res. 2004, 32, D189-D192.
42. Zhang, Y.; Skolnick, J. TM-align: A protein structure alignment algorithm based on the TM-score. Nucleic Acids Res. 2005, 33, 2302-2309.
43. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
44. Baki, A.; Bielik, A.; Molnar, L.; Szendrei, G.; Keseru, G. M. A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors. Assay Drug Dev. Technol. 2007, 5, 75-83.
45. ADP-Glo Kinase Assay Technical Manual: www.promega.com/tbs/.